i reading evelyn pringle latest article glaxosmithkline i excerpt moment struck me may also significant conflict interest points bear mentioning nonetheless much piece focused paxil glaxo latest escapade revealed october bloomberg news reported glaxo conducted recall paxil cr selective serotonin reuptake inhibitor antidepressant last month pills may lack active ingredient company warn patients may taking useless pills doctors told bloomberg patients either abruptly stop taking paxil get inactive pills face risk suicidal thoughts shooting pains flu like symptoms paxil cr pills highest dose sold cause severe withdrawal symptoms according dr stephen ellen psychiatrist university massachusetts medical school worcester true patients might gotten dummy pills without knowing outrageous said according glaxo fda knew problem approved limited recall plan fda spokeswoman susan cruzan told bloomberg know details september paxil cr recall incident even outrageous back march government cited glaxo exact wrongdoing fda department justice initiated seizure paxil cr tablets glaxo failed meet standards laid fda ensure product safety strength quality purity among violations noted fda finding tablets could split apart patients could receive portion tablets lacks active ingredient alternatively portion contains active ingredient intended controlled release effect glaxo selling unknown amount paxil without active ingredient letting anyone know fact receiving placebo oops granted paxil ai much effective placebo withdrawal effects certainly concern especially people know withdrawing i like piece frequent mentions baum hedlund law firm maybe folks firm really tireless consumer advocates i idea read bit infomercial firm i suppose makes sense context end article states written part paxil litigation monthly round sponsored baum hedlund pharmaceutical antidepressant litigation department y'all know i antidepressant fan club evidenced posts seems particular article comes across bit much favor lawsuits i suppose counterargument may avenues pursue recourse convince manufacturers change poor practices given fda toothless response i would rebuttal said i could find nothing really contradicted original report bloomberg found